<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Obesity Market on FinanClub</title>
    <link>https://finan.club/tags/obesity-market/</link>
    <description>Recent content in Obesity Market on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 12 Jan 2024 09:07:13 +0000</lastBuildDate><atom:link href="https://finan.club/tags/obesity-market/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PFE</title>
      <link>https://finan.club/us/pfe/</link>
      <pubDate>Fri, 12 Jan 2024 09:07:13 +0000</pubDate>
      
      <guid>https://finan.club/us/pfe/</guid>
      <description>score:129
Chances: Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. Amgen has an experimental dual mechanism obesity drug in mid-stage trials with hopes for fewer side effects and less frequent dosing than competitors. Risks: Pfizer stock remains under pressure despite becoming one of the biggest names of the pandemic, indicating potential market uncertainty.</description>
    </item>
    
  </channel>
</rss>
